Meeting
2019 ASCO Annual Meeting
Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.
Authors
Bimal Bhindi
University of Calgary, Calgary, AB, Canada
Bimal Bhindi , Jeffrey Graham , Connor Wells , Frede Donskov , Felice Pasini , Jae-Lyun Lee , Naveen S. Basappa , Aaron Richard Hansen , Lori Wood , Christian K. Kollmannsberger , Ravindran Kanesvaran , Takeshi Yuasa , D. Scott Ernst , Sandy Srinivas , Brian I. Rini , I. Alex Bowman , Sumanta K. Pal , Toni K. Choueiri , Daniel Yick Chin Heng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4578)
DOI
10.1200/JCO.2019.37.15_suppl.4578
Abstract #
4578
Poster Bd #
404
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Optimal timing of delayed cytoreductive nephrectomy in metastatic renal cell carcinoma during the immunotherapy era.
First Author: Insija Ilyas Selene
Poster
2021 Genitourinary Cancers Symposium
Prognostic value of simple blood biomarkers of systemic inflammation for metastatic renal cell carcinoma (mRCC) patients who undergo cytoreductive nephrectomy (CNx).
First Author: Jigi Moudgil-Joshi
Poster
2018 ASCO Annual Meeting
CABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC).
First Author: Guillermo de Velasco
Poster
2017 ASCO Annual Meeting
TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents.
First Author: Paolo Grassi